Skip to content

Side-by-side research guides

Peptide Comparisons

Head-to-head comparisons of the most-asked peptide pairings in current research — receptor targets, published trial data, and when each side is the right research tool.

Semaglutide
vs
Tirzepatide

Semaglutide vs Tirzepatide: GLP-1 Mono vs Dual-Agonist Research

Comparison of Semaglutide and Tirzepatide as research compounds — structure, receptor targets, reported half-life, published trial programmes and regulatory status.

Read the comparison
BPC-157
vs
TB-500

BPC-157 vs TB-500: A Preclinical Comparison of Two Tissue-Model Peptides

Preclinical comparison of BPC-157 and TB-500 (Thymosin Beta-4 fragment) — structure, mechanism, reported half-life, animal model types and readouts, and where the two literatures overlap.

Read the comparison
CJC-1295
vs
Ipamorelin

CJC-1295 vs Ipamorelin: GHRH Analog vs Ghrelin Mimetic

Preclinical comparison of CJC-1295 and Ipamorelin — receptor targets, reported effects on GH pulse amplitude and frequency, reported half-life, and where the two literatures overlap.

Read the comparison
Ipamorelin
vs
GHRP-6

Ipamorelin vs GHRP-6: Selectivity vs Potency in Ghrelin Mimetics

Preclinical comparison of Ipamorelin and GHRP-6 — structure, receptor selectivity, reported cortisol, prolactin and appetite readouts, and reported half-life.

Read the comparison
GHK-Cu
vs
BPC-157

GHK-Cu vs BPC-157: Dermal Models vs Soft-Tissue Models

Preclinical comparison of GHK-Cu and BPC-157 — copper-peptide dermal biology vs a gastric-derived peptide in soft-tissue models, mechanisms, readouts and where the two literatures overlap.

Read the comparison
Retatrutide
vs
Tirzepatide

Retatrutide vs Tirzepatide: Triple vs Dual Incretin Agonism

Comparison of Retatrutide (GLP-1 / GIP / glucagon triple agonist) and Tirzepatide (GLP-1 / GIP dual agonist) — receptor architecture, reported half-life, published trial programmes and regulatory status.

Read the comparison
Retatrutide
vs
Semaglutide

Retatrutide vs Semaglutide: Triple Agonist vs the GLP-1 Reference

Comparison of Retatrutide (GLP-1 / GIP / glucagon triple agonist) and Semaglutide (GLP-1 mono-agonist) — receptor architecture, reported half-life, published trial programmes and regulatory status.

Read the comparison

Ready to order

Research peptides featured in these comparisons

Browse all →

Comparison guides are summaries of research-context differences — receptor targets, mechanism and published trial data. All compounds are chemical reagents for laboratory analysis. See our Terms & Conditions.